Abstract
Vasopressin antagonists are a class of neurohormonal antagonists with applications in both the short-term and long-term management of patients with acute decompensated heart failure (ADHF). The pharmacologic effects of vasopressin antagonists include changes in fluid balance and hemodynamics that may improve symptoms and outcomes in patients hospitalized with ADHF. With chronic therapy, vasopressin antagonists offer the potential to improve outcomes through a variety of mechanisms, including more effective treatment of congestion, preservation or improvement of renal function, or a reduction in the use of concomitant loop diuretic therapy. Several vasopressin antagonists are currently in advanced clinical trials for the treatment of ADHF, chronic stable heart failure, and hyponatremia.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 131-139 |
| Number of pages | 9 |
| Journal | Current heart failure reports |
| Volume | 2 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 2005 |
Funding
Dr. Orlandi and Dr. Zimmer are employed by Otsuka Maryland Research Institute. Dr. Gheorghiade is a consultant for, and receives research support from, Otsuka Maryland Research Institute. Otsuka Maryland Research Institute is the developer of tolvaptan.
ASJC Scopus subject areas
- Emergency Medicine
- Cardiology and Cardiovascular Medicine
- Physiology (medical)